An observational study in Alzheimer Disease, Mild Cognitive Impairment and Healthy, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Alzheimer Disease by Mayo Clinic — 8 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Mayo Clinic.
Among the 21 studies in Alzheimer Disease by Mayo Clinic, this one is one of 2 that started in 2023, is one of 4 observational ones, and was the 19th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →8 of the 21 studies in Alzheimer Disease by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 50–95 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
Mayo Clinic · Sites in United States
Ages 50–90
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 57 across the 17 interventional studies, 195 across the 4 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
7 of the studies in Alzheimer Disease by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04785300Mayo ClinicALSENLITE: Senolytics for Alzheimer's Disease | 2026-12 |
| NCT04002583Mayo Clinic48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease | 2026-12 |
| NCT04099823Mayo ClinicMR Evaluation of Cerebrospinal Fluid (CSF) Dynamics | 2027-01 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
| NCT00950430Mayo ClinicImaging of Brain Amyloid Plaques in the Aging Population | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 21 studies in Alzheimer Disease by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to further investigate the potential of brain stiffness as a novel biomarker for Alzheimer's disease.
Due to shifting demographics, the prevalence of dementia continues to increase in the population. To mitigate the effects of dementia will require new treatments working jointly with new methods for earlier and more sensitive diagnosis of the diseases. Magnetic resonance elastography (MRE) is a noninvasive technique for measuring tissue stiffness. MRE is a three-step process beginning with the introduction of shear waves into the tissue of interest with an external vibration source. The shear waves are imaged with a phase-contrast MRI pulse sequence and the resulting wave images are mathematically inverted to calculate tissue stiffness.
Preliminary data indicate that global brain stiffness is highly reproducible and that Alzheimer's disease causes a decrease in brain stiffness when compared to age- and gender-matched cognitively normal controls. The purpose of the proposed work is to further investigate the potential of brain stiffness as a novel biomarker for Alzheimer's disease. A comparison between brain stiffness and existing Alzheimer's disease biomarkers will help determine the biological basis of the observed stiffness change and in time may improve the sensitivity of Alzheimer's disease diagnosis and grading.
Subjects will be selected from Mayo Alzheimer's Disease Research Center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for Mild Cognitive Impairment Subjects:
Inclusion Criteria for Alzheimer's Disease Subjects:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will have a magnetic resonance elastography (MRE) performed.
Diagnostic Test: Magnetic Resonance Elastography (MRE)
Subjects will have a magnetic resonance elastography (MRE) performed.
Diagnostic Test: Magnetic Resonance Elastography (MRE)
Subjects will have a magnetic resonance elastography (MRE) performed.
Diagnostic Test: Magnetic Resonance Elastography (MRE)
Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.
Shear Stiffness
Brain stiffness measured by the magnetic resonance elastography (MRE) reported in Kilopascal (kPa)
Time frame: Baseline
Joint mechanical-diffusion
MRE-based measurement of white matter regions of the brain
Time frame: Baseline
Plan to share: No
Started Oct 2023 (actual). Primary completion is estimated for Nov 2027, 49 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 49 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.